-
BIO Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Bio-Rad Laboratories (BIO)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 412.19 mm | 412.19 mm | 412.19 mm | 412.19 mm | 412.19 mm | 412.19 mm |
Cash burn (monthly) | (no burn) | 3.84 mm | (no burn) | 83.77 mm | (no burn) | (no burn) |
Cash used (since last report) | n/a | 15.42 mm | n/a | 335.93 mm | n/a | n/a |
Cash remaining | n/a | 396.77 mm | n/a | 76.26 mm | n/a | n/a |
Runway (months of cash) | n/a | 103.2 | n/a | 0.9 | n/a | n/a |
13F holders | Current |
---|---|
Total holders | 424 |
Opened positions | 66 |
Closed positions | 74 |
Increased positions | 128 |
Reduced positions | 162 |
13F shares | Current |
---|---|
Total value | 5.56 tn |
Total shares | 18.73 mm |
Total puts | 13.90 k |
Total calls | 19.50 k |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
BlackRock | 1.93 mm | $645.71 bn |
Vanguard | 1.91 mm | $638.26 bn |
Van Eck Associates | 1.30 mm | $436.86 mm |
Veritas Asset Management | 1.09 mm | $363.51 bn |
First Eagle Investment Management | 713.00 k | $238.56 bn |
Select Equity | 708.45 k | $237.03 bn |
Dimensional Fund Advisors | 654.43 k | $218.96 bn |
STT State Street | 635.92 k | $212.76 bn |
Earnest Partners | 605.55 k | $202.60 bn |
Millennium Management | 583.80 k | $195.33 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Oct 24 | Jonathan P. DiVincenzo | RSU Bio-Rad A Common Stock | Grant | Acquire A | No | No | 0 | 7,478 | 0.00 | 7,478 |
20 Oct 24 | Sedat Evran | Bio-Rad A Common Stock | Payment of exercise | Dispose F | No | No | 346.37 | 335 | 116.03 k | 853.14 |
20 Oct 24 | Sedat Evran | Bio-Rad A Common Stock | Option exercise | Acquire M | No | No | 0 | 1,044 | 0.00 | 1,188.14 |
20 Oct 24 | Sedat Evran | RSU Bio-Rad A Common Stock | Option exercise | Dispose M | No | No | 0 | 1,044 | 0.00 | 3,132 |
6 Sep 24 | Edwards Jeffrey L | RSU Bio-Rad A Common Stock | Grant | Acquire A | No | No | 0 | 308 | 0.00 | 308 |
6 Sep 24 | Roop Kalyan Lakkaraju | RSU Bio-Rad A Common Stock | Grant | Acquire A | No | No | 0 | 6,143 | 0.00 | 6,143 |